Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q15822

UPID:
ACHA2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q15822; A8KAX3; B4DK19; J3KMY9; Q9HAQ3

BACKGROUND:
Neuronal acetylcholine receptor subunit alpha-2 is essential for cholinergic neurotransmission, responding to acetylcholine by opening a channel that allows ions to pass through the cell membrane. This action is fundamental for neuronal communication.

THERAPEUTIC SIGNIFICANCE:
Given its association with conditions like Epilepsy, nocturnal frontal lobe, 4, and benign familial infantile seizures, the Neuronal acetylcholine receptor subunit alpha-2 represents a promising target for developing treatments for these neurological diseases. Its critical function in the nervous system underscores the therapeutic potential of modulating its activity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.